AN2 Therapeutics (ANTX) Current Assets (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Current Assets for 6 consecutive years, with $87.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets rose 25.78% year-over-year to $87.5 million; the TTM figure through Mar 2026 stood at $87.5 million (up 25.78% YoY), while the FY2025 annual figure was $59.9 million, down 30.52% from the prior year.
• Current Assets grew to $87.5 million in Q1 2026 per ANTX's latest filing, from $59.9 million in the prior quarter.
• Across five years, Current Assets topped out at $126.4 million in Q3 2023 and bottomed at $59.9 million in Q4 2025.
• Historically, Current Assets has averaged $95.5 million across 5 years, with a median of $98.2 million in 2023.
• Annual changes were most pronounced in 2022 — Current Assets surged 64.08% — and 2025, when it plunged 40.2%.
• AN2 Therapeutics' Current Assets stood at $98.6 million in 2022, then advanced by 12.05% to $110.5 million in 2023, then declined by 21.94% to $86.3 million in 2024, then sank by 30.52% to $59.9 million in 2025, then jumped by 45.97% to $87.5 million in 2026.
• Business Quant data shows ANTX's Current Assets at $87.5 million in Q1 2026, $59.9 million in Q4 2025, and $64.0 million in Q3 2025.